Breast cancer: Treatment decisions on basis of biomarker-based test can be harmful

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the pros and cons of biomarker-based tests to inform decisions about adjuvant chemotherapy for patients with a certain type of breast cancer, i.e., first-time, hormone receptor-positive and HER2/neu-negative breast cancer.

You can now grab 3-D pictures out of thin air | Science News
- On the Hunt for the Periphery of the Periodic Table: A Journey to Discover the Island of Enhanced Stability - Arya Chandran
- New: Judge Stops Congress From Defunding Planned Parenthood, Outrage and Confusion Follow
- 2025 Is The Year Sci-Fi Movies Go Full Dark, No Stars - Drew Dietsch
- The Future of Generative AI: Stable Video Diffusion - Michael Terry
- 5 Best Debt Relief Companies of July 2025
- Trump Issues Order To End Green Energy Gravy Train, Cites National Security - Audrey Streb

Five Quality Stocks To Buy Now
- 12 must-have gadgets for college students in 2025 - Valentina Palladino
- Loki’s Return in Avengers: Doomsday Changes Everything—Tom Hiddleston Confirms on Jimmy Kimmel Live - Staff
- Chick-fil-A delivers food by boat
- New research indicates one sport is even better for your body than running or swimming
- Checking in on Argentina After a Very Milei Year and a Half
- Apple Vision Pro: A Dive into the World of Spatial Computing - Michael A. Medeiros